Meeder Asset Management Inc. increased its position in Centogene (NASDAQ:CNTG) by 204.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,198 shares of the company’s stock after buying an additional 3,492 shares during the quarter. Meeder Asset Management Inc.’s holdings in Centogene were worth $54,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC lifted its holdings in shares of Centogene by 204.6% in the first quarter. Millennium Management LLC now owns 301,406 shares of the company’s stock valued at $3,656,000 after buying an additional 202,441 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Centogene by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 22,996 shares of the company’s stock valued at $279,000 after purchasing an additional 1,151 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Centogene during the first quarter valued at $579,000. BlackRock Inc. lifted its holdings in shares of Centogene by 1.1% during the first quarter. BlackRock Inc. now owns 433,268 shares of the company’s stock valued at $5,256,000 after purchasing an additional 4,737 shares during the last quarter. Finally, Platinum Investment Management Ltd. lifted its holdings in shares of Centogene by 8.6% during the first quarter. Platinum Investment Management Ltd. now owns 444,595 shares of the company’s stock valued at $5,393,000 after purchasing an additional 35,207 shares during the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.
Several equities research analysts recently issued reports on CNTG shares. Robert W. Baird increased their price objective on Centogene from $13.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 8th. SVB Leerink reaffirmed a “buy” rating and issued a $24.00 target price on shares of Centogene in a research report on Sunday, June 27th. Zacks Investment Research lowered Centogene from a “hold” rating to a “strong sell” rating in a research report on Friday, September 10th. BTIG Research reaffirmed a “buy” rating and issued a $23.00 target price on shares of Centogene in a research report on Sunday, June 20th. Finally, Credit Suisse Group dropped their target price on Centogene from $15.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, June 17th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $18.50.
Centogene (NASDAQ:CNTG) last issued its quarterly earnings data on Monday, September 6th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.11). The company had revenue of $62.49 million for the quarter, compared to analyst estimates of $38.53 million. Centogene had a negative net margin of 6.88% and a negative return on equity of 25.39%. As a group, analysts predict that Centogene will post -1.88 earnings per share for the current year.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Read More: Why is Cost of Capital Important?
Want to see what other hedge funds are holding CNTG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centogene (NASDAQ:CNTG).
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.